Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ivax generic Zyprexa ruling

Executive Summary

Ivax expects a decision on its challenge of Lilly's atypical antipsychotic Zyprexa (olanzapine) by year end, the generic firm said. "Our patent challenge trial on Zyprexa concluded in February 2004, and we expect a decision before the end of the year," Ivax President Neil Flanzraich stated during a Nov. 1 earnings call. An appellate court decision invalidating a GlaxoSmithKline patent for Paxil could boost Ivax' Zyprexa case (1"The Pink Sheet" May 3, 2004, p. 18). An Ivax patent challenge of Forest's antidepressant Lexapro begins in May 2005, Flanzraich noted...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS044939

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel